$10

Multiple Dates

Therapy and Research in Psychedelic Science (TRIPS) Seminar Series

Actions and Detail Panel

$10

Event Information

Share this event

Date and Time

Location

Location

Online Event

Event description
TRIPS focuses on educating healthcare professionals about the latest innovations in therapy and research in psychedelic science.

About this Event

TRIPS seminar series hosts speakers discussing scientifically-oriented presentations and discussions about psychedelics to educate healthcare professionals. This series was created to guide healthcare providers and students preparing to be professionals towards the most relevant, pragmatic, and essential information about psychedelic-assisted therapy, changing legal statuses, and harm reduction approaches in order to better serve clients and communities.

This seminar series is a fundraiser for our clinical trial of MDMA-assisted psychotherapy for social anxiety disorder that Portland Psychotherapy investigators plan to begin in the Fall of 2021. All proceeds after presenter remuneration will go to fund this clinical trial.

These presentations are hosted through Zoom. Each presentation will be approximately 30 minutes with a 30-minute discussion afterward. Presentations will be recorded and sent to anyone who registers for the event.

Upcoming Events:

December 11th, 2020 - Ethical and Legal Considerations in Providing Psychedelic Integration Therapy with Brian Pilecki, Ph.D. and Jason Luoma, Ph.D.

There is an increasing demand from clients seeking therapeutic support in their use of psychedelics as tools for personal growth and healing. However, many clinicians interested in psychedelic preparation and integration are unsure as to how to provide these services while psychedelics remain illegal. This webinar will outline legal and ethical frameworks relevant to providing therapy to clients around their use of psychedelics, as well as describe how harm reduction approaches are suitable for this new clinical area. We will outline the most common ethical and legal risks for therapists engaging in this work and steps to mitigate this risk. We also discuss common decision points and provide reflection questions for clinicians considering involvement in psychedelic integration therapy.

Jason Luoma, Ph.D. is CEO of Portland Psychotherapy in Portland, OR. His research focuses on shame, self-stigma, connection, self-compassion, and the application of ACT and psychedelic-assisted therapy to shame and self-criticism. He is currently organizing a clinical of MDMA-assisted psychotherapy for social anxiety disorder that looks like it will be the first trial of psychedelic-assisted therapy in the Pacific Northwest. He also recently organized a special section on psychedelic-assisted therapy and contextual behavioral science and is publishing a meta-analysis of outcomes of psychedelic-assisted therapy. He is also an internationally recognized trainer in ACT, former chair of the ACT training committee, and past president of the Association for Contextual Behavioral Science. He has over 50 publications including co-authoring two books: Learning Acceptance and Commitment Therapy and Values in Therapy: A Clinician’s Guide to Helping Clients Explore Values, Increase Psychological Flexibility and Live a More Meaningful Life. His work on shame and compassion can be read at www.actwithcompassion.com.

Dr. Brian Pilecki is a clinical psychologist at the Portland Psychotherapy that specializes in the treatment of anxiety disorders (OCD, generalized anxiety, social anxiety, panic disorder), trauma and PTSD, and matters related to the use of psychedelics. He completed a post-doctoral fellowship at The Warren Alpert Medical School of Brown University and practices from an orientation based in Acceptance and Commitment Therapy (ACT). He has been studying psychedelics for over 20 years, including earning an M.A. in East-West Psychology at the California Institute of Integral Studies and attending numerous trainings and conferences. At Portland Psychotherapy he is involved in several research studies on psychedelics, such as a clinical trial investigating the use of MDMA to treat social anxiety and has published in the area of psychedelics and Acceptance and Commitment Therapy (ACT). He is also involved in public education and advocacy to reduce the stigma associated with psychedelic use.

____________________________________________________________________________________________

January 8th, 2021 - What's It Like to Trip? The Patient Experience in Psychedelic-Assisted Therapy with Brian Pilecki, Ph.D.

There has been a resurgence of interest in the use of psychedelic substances to treat mental health problems, largely due to strong outcome data of recent clinical trials investigating psychedelic-assisted therapy. While many are familiar with this research, there seems to be less clarity around what the patient experience is like. How does psychedelic-assisted therapy work? How do psychedelic experiences lead to positive change or improvement? This webinar will outline the patient experience in this new form of treatment, including what is like to attend preparation sessions, dosing sessions, and follow-up integration sessions with therapists. Experiences from patients who participated in clinical trials will be included to help illustrate how psychedelics helped them.

Dr. Brian Pilecki is a clinical psychologist at the Portland Psychotherapy that specializes in the treatment of anxiety disorders (OCD, generalized anxiety, social anxiety, panic disorder), trauma and PTSD, and matters related to the use of psychedelics. He completed a post-doctoral fellowship at The Warren Alpert Medical School of Brown University and practices from an orientation based in Acceptance and Commitment Therapy (ACT). He has been studying psychedelics for over 20 years, including earning an M.A. in East-West Psychology at the California Institute of Integral Studies and attending numerous trainings and conferences. At Portland Psychotherapy he is involved in several research studies on psychedelics, such as a clinical trial investigating the use of MDMA to treat social anxiety and has published in the area of psychedelics and Acceptance and Commitment Therapy (ACT). He is also involved in public education and advocacy to reduce the stigma associated with psychedelic use.

____________________________________________________________________________________________

February 12th, 2021 - Returning From All: Integrating 5-MeO-DMT Experiences in Psychotherapy with Rafael Lancelotta, M.S.

While there has been positive press about the potential benefits of 5-MeO-DMT use in the general population, there have been many cases in which people have not been adequately prepared, used too much, or did not have adequate support following their experience. In this presentation, Rafael will talk about protective measures that have been studied in his research and discuss how therapists might approach supporting clients after an experience that has left them dysregulated and overwhelmed.

Rafael Lancelotta is a somatic-focused, trauma-informed therapist working in private practice in Golden, Colorado, who has supported clients' use of cannabis and ketamine to facilitate the therapeutic process. He has authored, co-authored, helped design, carry out, and present numerous published research studies on 5-MeO-DMT use in the general population. He serves as a Founding Board Member and Secretary of the Source Research Foundation, a foundation which aims to connect, inspire, and support students who study all contexts of psychedelic use, and to develop a virtual collaboratory of students, scientists, and community members who are passionate about psychedelic science. He received his Master's degree in Mental Health Counseling from the University of Wyoming. He is interested in the use of psychedelics towards greater levels of resiliency, mental health, and openness. He is also interested in the investigation of techniques used in the counseling relationship that may deepen and enhance the benefits of psychedelic-assisted therapy and its integration. He is passionate about conversations about accessibility to psychedelic-assisted therapies to all people that may benefit as well as helping to raise awareness as to the responsible clinical applications of psychedelics/entheogens. He hopes to continue working to help develop evidence-based practices for psychedelic-assisted therapy sessions and integration to empower individuals to make lasting positive changes in their lives and in their communities. He is also the administrator of 5meodmt.org, which is a forum dedicated to forming community discussions on harm reduction, integration, and safe practices around 5-MeO-DMT.

____________________________________________________________________________________________

March 12th, 2021 - What does Psilocybin-Assisted Therapy for Depression Look Like? A Clinical Case Presentation based on a Recent Clinical Trial from Johns Hopkins with Alan K. Davis, Ph.D.

This talk will integrate findings from a recent controlled trial of psilocybin therapy for people diagnosed with Major Depressive Disorder with a case report from a patient enrolled in the trial. The efficacy of this intervention will be contextualized within the scope of the patient’s experiences and a description of the therapeutic process involved in preparing for and integrating psilocybin experiences as part of therapy.

Dr. Alan K Davis is an Assistant Professor of Social Work at The Ohio State University and Adjunct Assistant Professor in the Center for Psychedelic and Consciousness Research at Johns Hopkins University. Dr. Davis’s clinical experience includes working with people diagnosed with trauma-based psychological problems such as addiction, PTSD, depression, and anxiety. His clinical expertise includes providing evidenced-based treatments such as motivational interviewing, cognitive behavioral therapy, acceptance and commitment therapy, and psilocybin-assisted psychotherapy. Consistent with his clinical interests, his research interests, and expertise focus on contributing to the knowledge of and ability to help those suffering with substance use and mental health problems, understanding how to improve clinical outcomes through examining new treatments and developing ways to conceptualize substance use and mental health problems through a strengths-based approach. He recently completed a clinical trial of psilocybin therapy for major depressive disorder and current trials include exploring this treatment for patients with co-occurring alcohol use disorder and depression and patients with anorexia. He actively explores topics related to naturalistic psychedelic use among several populations including people of color who have experienced racial trauma, Spanish-speaking people, and people who use novel psychedelics such as 5-MeO-DMT.

___________________________________________________________________________________________

April 9th, 2021 - Gregory Wells, Ph.D.

Presentation description to be announced.

____________________________________________________________________________________________

May 14th, 2021 - Research on MDMA and Psychedelic-Assisted Therapy: An Overview of the Evidence for Clinicians with Jason Luoma, Ph.D.

This presentation is for those who want to understand the breadth of the existing research on the effectiveness of psychedelic and MDMA-assisted therapy. We will review all existing placebo-controlled randomized trials, as well as open trials. Much of this presentation is based on a recent meta-analysis that this presenter published. Attendees will walk away with a broad understanding of the strength and breadth of the existing data on psychedelic assisted therapy and how it compares to other treatments.

Jason Luoma, Ph.D. is CEO of Portland Psychotherapy in Portland, OR. His research focuses on shame, self-stigma, connection, self-compassion, and the application of ACT and psychedelic-assisted therapy to shame and self-criticism. He is currently organizing a clinical of MDMA-assisted psychotherapy for social anxiety disorder that looks like it will be the first trial of psychedelic-assisted therapy in the Pacific Northwest. He also recently organized a special section on psychedelic-assisted therapy and contextual behavioral science and is publishing a meta-analysis of outcomes of psychedelic-assisted therapy. He is also an internationally recognized trainer in ACT, former chair of the ACT training committee, and past president of the Association for Contextual Behavioral Science. He has over 50 publications including co-authoring two books: Learning Acceptance and Commitment Therapy and Values in Therapy: A Clinician’s Guide to Helping Clients Explore Values, Increase Psychological Flexibility and Live a More Meaningful Life. His work on shame and compassion can be read at www.actwithcompassion.com.

____________________________________________________________________________________________

June 11th, 2021 - Nathan Gates, M.A.

Presentation description to be announced.

____________________________________________________________________________________________

Get Our Newsletter

Additional events for 2021 will be announced as they are scheduled. If you would like to stay up to date on information about TRIPS, you can join our newsletter here.

Share with friends

Location

Online Event

Save This Event

Event Saved